Practice Operations · For practice managers
How to Audit Biologic Vendors for FDA 361 HCT/P Compliance
Published November 20, 2026
- 361 HCT/P Qualification Criteria
- Four Core Standards
- Establishment Registration Cadence
- Annual Verification
- Primary Audit Risk Drivers
- Processing & Claims
Under 21 CFR 1271.10(a), a tissue product must simultaneously meet minimal manipulation, homologous use, no prohibited combination articles, and no systemic or metabolic cell dependency to avoid 351 drug regulation.
Under 21 CFR 1271.21, tissue establishments must register with the FDA and update their registration annually in December, giving practice managers a reliable cadence for re-auditing active vendors.
Regulatory enforcement actions in the regenerative sector most frequently stem from two areas: enzymatic or mechanical processing that exceeds minimal manipulation, and promotional claims that exceed homologous structural use.
Auditing biologic vendors for FDA 361 HCT/P compliance requires cross-referencing supplier FDA Form 3356 filings, validating donor eligibility determination records under 21 CFR Part 1271 Subpart C, and confirming that all tissue processing strictly maintains minimal manipulation without systemic metabolic activity. For clinical practices procuring regenerative biologics, relying solely on vendor sales collateral creates substantial regulatory liability, product recall exposure, and licensure risk. This operational framework provides the exact document request checklist, lot-release validation steps, and red flags practice managers need to thoroughly qualify tissue processors.
Understanding the Regulatory Baseline: 361 vs. 351 Products
Before initiating a vendor audit, procurement teams must understand the fundamental distinction within the FDA’s regulatory framework under 21 CFR Part 1271.
Products regulated solely under Section 361 of the Public Health Service (PHS) Act are exempt from premarket approval (such as a Biologics License Application or Investigational New Drug application). To qualify as a 361 HCT/P, a product must meet four strict criteria concurrently:
- Minimal Manipulation: Processing must not alter the original relevant characteristics of structural tissue (e.g., amniotic membrane, Wharton's Jelly) or the relevant biological characteristics of cells.
- Homologous Use: The product must perform the same basic function or functions in the recipient as in the donor (e.g., serving as a protective covering or structural cushion), as reflected by the vendor's labeling and advertising.
- No Combination Articles: The tissue must not be combined with another article, with limited exceptions for water, crystalloids, or sterilizing, preserving, or storage agents.
- No Systemic Effect: The product must not have a systemic effect and cannot depend on the metabolic activity of living cells for its primary function (unless intended for autologous use, first- or second-degree blood relatives, or reproductive use).
If a biologic vendor’s processing method alters the tissue beyond minimal manipulation—such as enzymatically digesting structural tissue into a cellular suspension—or if the vendor markets the product to treat specific systemic diseases, the product defaults to a Section 351 drug or biological product. Distributing a 351 product without an approved BLA or active IND is a federal violation.
The Biologic Vendor Audit Checklist for Practice Managers
When evaluating a new manufacturer or distributor for orthopedic, pain management, or aesthetic service lines, practice administrators should require a formal compliance dossier before signing a purchasing agreement. Use the following checklist to standardize your procurement review:
- Active FDA Establishment Registration (FEI Number): Request the manufacturer’s FDA Establishment Identifier (FEI) and independently verify it in the FDA’s public Human Cell and Tissue Establishment Registration (HCTER) database. Confirm whether the entity is registered as a processor, packager, or distributor, and check that the registration status is currently active.
- FDA Inspection History and Warning Letters: Search the FDA’s online compliance database for the manufacturer and any parent companies. Look for Form 483s (inspectional observations), Untitled Letters, or Warning Letters issued over the past several years. Pay close attention to citations regarding current Good Tissue Practice (cGTP) deviations or unapproved drug claims.
- AATB Accreditation and State Licensing: Verify whether the processing lab holds accreditation from the American Association of Tissue Banks (AATB). While voluntary, AATB accreditation indicates adherence to industry-recognized standards for tissue banking. Additionally, verify required state-level tissue bank licenses (such as those from California, New York, Florida, or Maryland) and confirm that your distributor holds the appropriate state medical device or tissue distribution licenses.
- Donor Eligibility and Infectious Disease Screening: Review a sample Certificate of Analysis (CoA) and package insert. Ensure the vendor follows 21 CFR Part 1271 Subpart C for donor eligibility, including rigorous maternal medical history reviews for birth tissues and testing for relevant communicable disease agents (HIV, Hepatitis B and C, syphilis, WNV, Zika, and CMV where applicable) using FDA-licensed, approved, or cleared screening tests.
- Sterility and Processing Validation: Confirm how the final product is tested for sterility (e.g., USP <71> standards) and endotoxin levels. Ask the vendor to provide a clear, non-evasive summary of their processing steps to confirm the tissue has not undergone enzymatic digestion, mechanical micronization that destroys structural integrity, or culture expansion.
- Labeling and Marketing Material Review: Audit the vendor’s brochures, website, and sales decks. Under 21 CFR 1271.10(a)(2), the FDA evaluates "homologous use" based on the manufacturer's objective intent, which includes their promotional claims. If a vendor provides patient-facing brochures claiming their allograft "cures osteoarthritis" or "regenerates cartilage via live stem cells," they are violating 361 boundaries and exposing your clinic to regulatory scrutiny.
- Cold-Chain Logistics and Lot Traceability: Evaluate the operational workflow for shipping and receiving. Does the vendor use validated cryogenic or dry-ice shipping containers? Do they provide a clear mechanism for tracking allograft ID numbers from the donor to the recipient, as required by cGTP for adverse reaction reporting?
Red Flags in Vendor Responses
During the discovery phase, how a vendor responds to compliance inquiries is often as telling as the documents they provide. Practice managers should halt the onboarding process if they encounter the following red flags:
Misrepresenting "FDA Registered" as "FDA Approved"
A common compliance pitfall occurs when sales representatives claim their amniotic or umbilical cord product is "FDA approved." True 361 HCT/Ps are never FDA approved or cleared; the facility is merely registered with the FDA. Using registration status to imply product endorsement violates federal regulations.
Relying on Unverified "TRG" Letters
Some vendors present letters from the FDA’s Tissue Reference Group (TRG) as definitive proof of compliance. However, TRG letters are non-binding, informal opinions based solely on the specific information submitted by the manufacturer. If a vendor alters their processing method or expands their marketing claims after receiving a TRG letter, the opinion is no longer protective.
Promoting High Live MSC Counts in Allogeneic Products
If a vendor markets an off-the-shelf allogeneic product by emphasizing millions of live, metabolically active Mesenchymal Stem Cells (MSCs) as the primary mechanism of action, they are directly contradicting the fourth criterion of 21 CFR 1271.10(a). For an allogeneic product to remain in the 361 category, its primary function cannot depend on the metabolic activity of living cells.
Clinical Perspective: Aligning Physician Expectations with Operational Compliance
While the practice manager handles vendor vetting, contracting, and supply chain logistics, the treating physicians must be integrated into the compliance framework. For regenerative medicine doctors and specialists, clinical efficacy and patient safety are paramount, yet clinical enthusiasm must align with regulatory boundaries.
Physicians should understand that when a vendor claims a birth tissue product is a 361 HCT/P, the legal mechanism of action is structural—such as serving as a barrier, cover, or cushion—rather than cellular or metabolic. During patient consultations and informed consent processes, clinicians should avoid adopting aggressive vendor sales language that promises tissue regeneration or disease modification.
Furthermore, clinicians and administrators should collaborate to ensure the practice’s internal clinical protocols—including how the product is thawed, prepared, and combined with other medical supplies or autologous blood products like PRP—do not inadvertently cross the line into creating an unapproved combination product at the point of care. All clinical decisions regarding patient selection and administration belong solely to the licensed treating clinician, supported by accurate, compliant product documentation.
Operationalizing Ongoing Vendor Management
Compliance is not a one-time onboarding task. Once a biologic vendor is approved, practice managers should implement standard operating procedures (SOPs) for receiving and documentation:
- Receiving Inspections: Train clinical staff to inspect every shipment upon arrival. Staff must verify that dry ice or phase-change materials remain intact, check temperature loggers if included, and ensure the vial lot numbers match the enclosed tissue tracking forms and Certificates of Analysis.
- Tissue Tracking Logs: Maintain a centralized, HIPAA-compliant log (physical or integrated into the EHR) that records the vendor name, unique tissue identification number, expiration date, date of administration, and recipient patient ID. Most reputable processors provide pre-paid return labels or digital portals to register the recipient card back to the tissue bank.
- Annual Re-Verification: Set a calendar reminder to check the FDA HCTER database and Enforcement Report annually for all active suppliers. Regulatory statuses can change rapidly following an FDA inspection.
What This Means for Your Practice
Implementing a structured biologic vendor audit protects your practice’s medical licenses, reputation, and financial stability. To formalize your procurement compliance this quarter, take these concrete steps:
- Inventory Current Suppliers: List all biologics currently in your clinic’s freezer or supply closet and pull the corresponding vendor files.
- Build a Compliance Binder: Request updated FEI numbers, AATB certificates, and sample package inserts from every current and prospective supplier, and verify their status in the FDA database.
- Audit Your Practice Marketing: Review your clinic’s website, social media, and patient intake forms to ensure your team has not inadvertently copied non-compliant vendor claims regarding stem cells or guaranteed clinical outcomes.
- Partner with Vetted Distributors: Work with established medical distributors who conduct upstream due diligence on their manufacturing partners.
At Dallas Regenerative Solutions, we prioritize regulatory transparency and supply chain integrity, working exclusively with licensed providers to deliver compliant regenerative technologies and biologics. If your practice is evaluating its current biologic procurement workflow or expanding its service lines, contact our team to schedule an operational consultation.
Frequently asked questions
- How do I check if a biologic vendor is registered with the FDA?
- You can verify a vendor's registration by searching the FDA's public Human Cell and Tissue Establishment Registration (HCTER) database online. Request the manufacturer's FDA Establishment Identifier (FEI) number and confirm that their registration status is marked as 'Active' for the specific tissue types and functions (such as processing or distributing) they provide.
- What is the difference between a 361 and a 351 biologic product?
- A Section 361 HCT/P is regulated solely under the Public Health Service Act and 21 CFR Part 1271, meaning it is minimally manipulated, intended for homologous use, and does not require premarket FDA approval. If a tissue product fails to meet all four criteria under 21 CFR 1271.10(a), it is regulated as a Section 351 biological product or drug, which legally requires an approved Biologics License Application (BLA) or an active Investigational New Drug (IND) application before distribution.
- Are FDA 361 HCT/P biologics 'FDA Approved'?
- No, true 361 HCT/P products are not FDA approved or cleared, because they are exempt from the premarket review process required for drugs and devices. Instead, the manufacturing facility is registered with the FDA and must comply with current Good Tissue Practice (cGTP) regulations; any vendor claiming their 361 product is 'FDA approved' is misrepresenting its regulatory status.
- Why do vendor marketing claims matter during a compliance audit?
- Under 21 CFR 1271.10(a)(2), the FDA determines whether a product meets the 'homologous use' requirement based on the manufacturer's objective intent, which is directly reflected in their labeling, advertising, and promotional materials. If a vendor markets a structural allograft to treat specific systemic diseases or regenerate tissue, those claims can reclassify the product as an unapproved 351 drug, creating regulatory exposure for both the vendor and the purchasing clinic.
- What documentation should accompany every biologic shipment to our clinic?
- Every biologic shipment should include a packing slip, a Certificate of Analysis (CoA) or Certificate of Compliance confirming donor eligibility and sterility testing, the official package insert detailing instructions for use, and a tissue tracking record. Your clinical staff should log the unique allograft identification number into the patient's chart and return the tracking verification to the tissue bank to maintain chain-of-custody compliance.
